Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
October 2012
Features
Editorial
Synthetic Cathinones (‘Bath Salts’)
Legal and Health Care Challenges
The growing abuse of toxic stimulants known as “bath salts” can cause psychosis and possibly death. Raising awareness of the dangers through patient counseling and community outreach programs will be important—especially efforts aimed at young people.
Jennifer A. Gershman, PharmD, CPh; and Andrea D. Fass, PharmD
State Cutbacks to Medicaid May Hit Hospitals Hard
New Federal Reductions Might Compound the Stress
Hospitals, low-income families, and disabled individuals who rely on Medicaid funding will be struggling financially if the government reduces its outlays to the states by $800 billion over the next 10 years in order to reduce the federal deficit.
Stephen Barlas
Pregabalin and Simvastatin
First Report of a Case of Rhabdomyolysis
A 70-year-old man with a history of fibromyalgia, type-2 diabetes mellitus, hypercholesterolemia, and chronic low back pain presented to the emergency department with altered mental status, limb weakness, twitching, and slurred speech. The authors sought to determine whether his rhabdomyolysis resulted from an adverse reaction associated with pregabalin and simvastatin.
Michele B. Kaufman, PharmD; and Mary Choy, PharmD
The Nanomedicine Revolution, Part 2
Current and Future Clinical Applications
Although many nanotherapeutic and nanodiagnostic agents are in use and have the potential to improve health care, many barriers have impeded the development and availability of these products. Despite these impediments, it is expected that nanomaterials will become an integral part of mainstream medicine.
C. Lee Ventola, MS
European Society of Cardiology Congress 2012
Topics include antiplatelet drugs for acute coronary syndrome, renal denervation for hypertension, contrast-induced nephropathy, “e-cigarettes,” and resistant hypertension.
Walter Alexander
Departments
Medication Errors
‘Inattentional Blindness’
What Captures Your Attention?
Many mistakes can result from ‘inattentional blindness.’
Matthew Grissinger, RPh, FASCP
Prescription: Washington
‘Gray Market’ Not Such a Gray Area Anymore
Why Hospitals Are Paying Exorbitant Drug Prices
Hospitals are paying exorbitant prices for drugs because of an insidious “gray market” pipeline.
Stephen Barlas
New Drugs/Drug News/New Medical Devices
FDA approvals, drug indications, and updates
Pharmaceutical Approval Update
Truvada for HIV prevention, Xtandi for metastatic castration-resistant prostate cancer, and Marqibo, a vincristine liposome injection for acute myelogenous leukemia
Marvin M. Goldenberg, PhD, RPh, MS
Drug Forecast
Ticagrelor (Brilinta), an Antiplatelet Drug for Acute Coronary Syndrome
RaeAnne Fuller, PharmD; and Benjamin Chavez, PharmD, BCPP
